An experimental medical implant developed by researchers at ETH Zurich converts excess blood sugar into a harmless byproduct using an electrically powered catalyst. Tested over six weeks in mice with diabetes and obesity, the wireless device stabilized blood glucose levels and promoted average weight loss of 10%.
Diabetes affects roughly 790 million people globally, while more than 1 billion individuals live with obesity. Among those diagnosed with type 2 diabetes, about 90% are also overweight or living with obesity.
These conditions frequently intersect with insulin resistance, a state where cells fail to respond properly to insulin and cannot clear sugar from the bloodstream effectively. While the body initially pumps out extra insulin to compensate, it eventually falls behind, while the liver converts surplus glucose into fat stores that drive further weight gain.
Standard medical management relies on lifestyle changes alongside long-term medications such as metformin to lower blood sugar or GLP-1 receptor agonists to curb appetite. ETH Zurich researchers chose a different route by aiming directly at the glucose itself through an inorganic, electrically driven chemical reaction.
Wireless Reactor Converts Blood Glucose Into Gluconate
Described in a study published in the journal Science, the inch-long reactor transforms glucose into a harmless byproduct called gluconate using an electrically powered catalyst. This conversion takes place at an electrode coated with gold and platinum nanoparticles embedded inside graphite felt.
Unlike earlier experimental configurations that depended on living cells or biological enzymes, this system uses inorganic materials. The implant operates wirelessly, drawing both power and operational signals from an ordinary smartphone or smartwatch.
The device emits low-frequency radio energy, which the implant’s internal electronics convert into a stable direct current to trigger the catalytic reaction.
When paired with a continuous glucose monitor, the system creates a closed-loop feedback mechanism. The sensor tracks blood sugar in real time, and when readings climb, the phone adjusts the power sent to the implant.
When glucose levels settle back down within a normal range, the device reduces its output or switches off entirely. This feedback loop is designed to prevent the implant from driving a patient’s blood sugar down to dangerous lows.
Six-Week Tests Measure Results in Diabetic Mice and Large Beakers
To test how the hardware handles high volumes, the research team placed the catalyst inside a large beaker filled with 1.3 gallons, or 5 liters, of a sugary solution—an amount roughly equivalent to an adult human’s total blood volume. The equipment successfully processed the sugar load in the larger container.
Researchers then tracked the implant’s performance over six weeks in mice exhibiting both obesity and diabetes. Animals fitted with the device maintained much more stable blood sugar levels compared to untreated control groups.
Sparing the body from sudden glucose spikes altered metabolic chemistry toward fat burning, allowing the treated mice to lose an average of 10% of their body weight.
The system operated reliably during the animal trials, and the team found no evidence of electrical or heat-related tissue injury, noting that the hardware was well tolerated.
Clinical Hurdles Face Future Human Trials at ETH Zurich
Despite the promising results in rodents, the technology remains an early-stage experimental project rather than an approved clinical treatment. Animal experiments cannot guarantee that the hardware will prove equally safe or effective inside the complex physiological environment of a human patient.
Future development will require proving that the catalytic reaction can scale up to handle human metabolic demands over extended periods.
Researchers must also evaluate the long-term behavior of the gluconate byproduct as the body clears it through urine, alongside rigorous checks on chronic durability and implant safety.
The team is now working toward testing the device in additional lab animals before eventually moving to human clinical trials.
Investigators emphasize that the hardware is not a standalone fix for the underlying drivers of metabolic disease.
Instead, scientists view the technology as a potential future tool that might eventually complement conventional lifestyle interventions and existing medications.